← Leaderboards
Elliot Stieglitz
University Of California, San Francisco
$3,577,281
Attributed
$3,577,281
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $711.3K · FY2017–25$1M$750K$500K$250K$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,577,281 · 2
By mechanism
R37$2,677,641 · 1
K08$899,640 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of California, San Francisco
Same institution · by research overlap
- Bennett Penn$4,633,852
- Jeffery S Cox$28,484,342
- Emmanuelle Passegue$22,475,888
Others in their field
Other Emerging Leaders on “Nf1 Gene”
- Iwei Yeh · University Of California, San Francisco$3,072,504
- Lawrence Kwong · University Of Tx Md Anderson Can Ctr$2,526,118
- Rona Yaeger · Sloan-Kettering Inst Can Research$2,512,582
- Brian Kevin Stansfield · Augusta University$2,158,372
- Nan Yang · Icahn School Of Medicine At Mount Sinai$1,973,528
- Yang Yang-Hartwich · Yale University$1,677,880
Research focus
Nf1 GenePathway InteractionsMyeloproliferative DiseaseHigh RiskMutationOutcome PredictionDisease ProgressionImproved OutcomeEpigenetic ProcessHematopoietic Stem Cell TransplantationKras2 GeneCbl GeneLeadMutateAcute Myelocytic LeukemiaCombinatorialDisease-Free SurvivalChildChildhoodEfficacy TestingGenesGenome-WideJuvenile Myelomonocytic LeukemiaPatient-Focused Outcomes
Grant awards (9)
Implementation of an interventional, risk-adapted clinical trial for children with newly diagnosed juvenile myelomonocytic leukemia.$673,836
R37 · FY2025 · CA · contact PI
Implementation of an interventional, risk-adapted clinical trial for children with newly diagnosed juvenile myelomonocytic leukemia.$634,503
R37 · FY2024 · CA · contact PI
Implementation of an interventional, risk-adapted clinical trial for children with newly diagnosed juvenile myelomonocytic leukemia.$658,014
R37 · FY2023 · CA · contact PI
Implementation of an interventional, risk-adapted clinical trial for children with newly diagnosed juvenile myelomonocytic leukemia.$711,288
R37 · FY2022 · CA · contact PI
Targeting SETBP1 in Myeloproliferative Disorders$179,928
K08 · FY2021 · HL · contact PI
Targeting SETBP1 in Myeloproliferative Disorders$179,928
K08 · FY2020 · HL · contact PI
Targeting SETBP1 in Myeloproliferative Disorders$179,928
K08 · FY2019 · HL · contact PI
Targeting SETBP1 in Myeloproliferative Disorders$179,928
K08 · FY2018 · HL · contact PI
Targeting SETBP1 in Myeloproliferative Disorders$179,928
K08 · FY2017 · HL · contact PI